Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 55,500 shares, a drop of 42.2% from the January 31st total of 96,000 shares. Based on an average trading volume of 64,900 shares, the days-to-cover ratio is presently 0.9 days. Currently, 3.3% of the shares of the stock are sold short.

Lixte Biotechnology Stock Performance

Lixte Biotechnology stock traded down $0.10 during mid-day trading on Friday, hitting $1.30. 38,430 shares of the company traded hands, compared to its average volume of 90,078. Lixte Biotechnology has a one year low of $1.25 and a one year high of $4.40. The stock has a market cap of $2.92 million, a price-to-earnings ratio of -0.75 and a beta of -0.04. The stock has a fifty day moving average price of $2.10 and a 200-day moving average price of $1.96.

Institutional Investors Weigh In On Lixte Biotechnology

An institutional investor recently bought a new position in Lixte Biotechnology stock. TIAA Trust National Association purchased a new position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 101,834 shares of the company’s stock, valued at approximately $207,000. TIAA Trust National Association owned approximately 4.53% of Lixte Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 5.10% of the company’s stock.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.